Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF) is a leader in biofilm-disrupting technologies for advanced wound and scalp care. This page aggregates all official company announcements, providing stakeholders with timely updates on regulatory progress, product developments, and strategic initiatives.
Investors and industry professionals will find comprehensive coverage of FDA clearances, manufacturing partnerships, and global licensing agreements. Our curated news stream includes earnings reports, clinical advancements, and distribution expansions, ensuring you never miss critical developments affecting KNBIF's market position.
Key focus areas include updates about antimicrobial wound care solutions, scalp health innovations, and quality certifications like ISO 13485:2016. Bookmark this page for direct access to primary-source information about Kane Biotech's progress in combating biofilm-related health challenges worldwide.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) has released a video featuring President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga discussing the recently announced FB Dermatology S.R.L. acquisition. The video presentation covers FB Dermatology's technology, product portfolio, market presence, and regulatory approvals, along with potential synergies between the two companies. This follows the initial acquisition announcement made on November 12, 2024.
Kane Biotech (KNBIF) has entered into a binding term sheet to acquire FB Dermatology, an Italian company with operations in Italy and Australia. The acquisition includes FB's FLETECH technology portfolio, featuring products like LumiHeal®, Kleresca®, and Lumixa® for wound care and dermatology applications. The purchase price includes $200,000 in cash at closing, 6 million Kane shares, 6 million warrants at $0.25, and potential future payments of $920,000 and $1,380,000 at 18 and 36 months respectively. The transaction is expected to close by January 31, 2025, expanding Kane's global commercial reach and strengthening its wound care portfolio.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its participation in a multinational corporate collaboration project. The company is receiving advisory services and up to $75,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for this initiative.
The project aims to develop a Proof-of-Concept for Kane's DispersinB® Wound Gel. Kane will collaborate with one of the world's largest wound care companies over a six-month period. This collaboration is expected to accelerate the development of the DispersinB® Wound Gel technology.
In addition to this project, Kane Biotech recently secured advisory services and up to $200,000 in research and development funding from NRC IRAP to support the development of three additional products based on the company's revyve™ Antimicrobial Wound Gel technology.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its participation in several upcoming wound care conferences to showcase its revyve™ Antimicrobial Wound Gel and revyve™ Antimicrobial Wound Gel Spray products. The company will attend:
- Symposium on Advanced Wound Care (SAWC) in Las Vegas, Nevada (October 2-5, 2024)
- Wounds Canada National Hybrid Conference in London, Ontario (October 17-19, 2024)
- Canadian Burn Conference in Niagara-on-the-Lake, Ontario (October 18-20, 2024)
- Gulf Diabetic Foot Conference in Kuwait City, Kuwait (November 15-16, 2024)
At these events, Kane Biotech will present research on the antibiofilm properties of its products and have booth presence to demonstrate the scientific benefits of the revyve™ product line to wound care practitioners.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced the exercise of 5 million warrants at an exercise price of $0.10 per common share, resulting in total proceeds of $500,000. The company's President & CEO, Marc Edwards, stated that the shares are being held by long-term supporters of Kane. The proceeds from these warrant exercises will be utilized for general working capital purposes, providing the company with additional financial resources for its operations.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its second quarter 2024 financial results, highlighting a significant $10.4 million gain from the sale of STEM. Key financial highlights include:
- License and royalty income increased by 74% to $299,992
- Product and services revenue rose by 5% to $510,360
- Total revenue grew by 23% to $810,352
- Gross profit increased by 41% to $464,453
- Net income of $9,201,830 compared to a net loss of ($967,905) in Q2 2023
The company also reported several recent developments, including new distribution agreements, MDSAP Quality Certification, FDA removal of usage limitations on revyve™ Antimicrobial Wound Gel, and new funding from NRC IRAP for product development.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced the publication of a new review article on DispersinB® in the journal Pathogens. The article, authored by Dr. Jeffrey B. Kaplan, highlights the enzyme's broad-spectrum antibiofilm activity against over 25 bacterial species. Kane Biotech is also presenting research on its revyve™ Antimicrobial Wound Gel Spray at the Military Health System Research Symposium and the Symposium on Advance Wound Care. These presentations showcase the company's commitment to advancing biofilm science and developing potential treatments for chronic wound infections.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has signed a three-year distribution agreement with Qatar Datamation Systems (QDS) for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market. This marks Kane's second distribution agreement in the Middle East and fourth overall for revyve™.
The company has previously secured distribution agreements for revyve™ in the United Arab Emirates, United States, Colombia, Costa Rica, and Panama. Kane Biotech also plans to commercialize revyve™ in Canada following its recent ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced that it will release its second quarter 2024 financial results after market close on Thursday, August 29, 2024. Following the release, the company's management will host a conference call at 4:30 p.m. ET on the same day to review the financial results and discuss business developments during the period. Interested participants are required to register for the call using a provided link. It is recommended to join the call 10 minutes before the event, although pre-registration is available at any time. Additionally, a webcast of the call will be accessible on Kane Biotech's website in the Investor section at ir.kanebiotech.com.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has signed a three-year distribution agreement with Razan Medical & Surgical Equipment Trading for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market. This marks Kane's first distribution agreement in the Middle East and third overall for revyve™.
Hussain Malkawi, Managing Director of Razan Medical, expressed enthusiasm about introducing the product to benefit thousands of patients in the UAE. Kane's President & CEO, Marc Edwards, emphasized the company's commitment to commercialization and confidence in the partnership.
Kane has previously announced distribution agreements for revyve™ in the US, Colombia, Costa Rica, and Panama. The company also plans to commercialize the product in Canada following its recent ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.
